Perspective Therapeutics (CATX) Inventory (2011 - 2023)
Perspective Therapeutics' (CATX) quarterly Inventory came in at $1.0 million in Q3 2023, down 34.77% year-over-year from $1.6 million in Q3 2022, and down 7.4% quarter-over-quarter from $1.1 million in Q2 2023.
Analysis
Perspective Therapeutics (CATX) Inventory (2011 - 2023) Analysis & Trends
Perspective Therapeutics has disclosed Inventory across 13 years of filings, most recently posting $1.0 million for Q3 2023.
- In Q3 2023, Inventory fell 34.77% year-over-year to $1.0 million; the TTM figure through Sep 2023 stood at $1.0 million (down 34.77% YoY), while the FY2022 annual figure was $1.4 million, changed N/A from the prior year.
- Inventory came in at $1.0 million for Q3 2023 at Perspective Therapeutics, down from $1.1 million in the prior quarter.
- In the past five years, Inventory ranged from a high of $1.6 million in Q3 2022 to a low of $501000.0 in Q3 2019.
- Average Inventory over 5 years is $921842.1, with a median of $980000.0 recorded in 2021.
- Year-over-year, Inventory surged 65.37% in 2021 and sank 34.77% in 2023.
- Over 5 years, Inventory stood at $545000.0 in 2019, then climbed by 22.02% to $665000.0 in 2020, then surged by 60.6% to $1.1 million in 2021, then jumped by 31.93% to $1.4 million in 2022, then declined by 28.11% to $1.0 million in 2023.
- Per Business Quant data, the three most recent Inventory figures were $1.0 million in Q3 2023, $1.1 million in Q2 2023, and $1.4 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 6.22 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.95 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.77 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 3.08 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 371.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 280.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 97.11 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 2.38 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | 1.09 Mn |
| Mar 31, 2023 | 1.41 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 1.55 Mn |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 1.16 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 1.06 Mn |
| Jun 30, 2021 | 980,000.00 |
| Mar 31, 2021 | 731,000.00 |
| Dec 31, 2020 | 665,000.00 |
| Sep 30, 2020 | 641,000.00 |
| Jun 30, 2020 | 645,000.00 |
| Mar 31, 2020 | 580,000.00 |
| Dec 31, 2019 | 545,000.00 |
| Sep 30, 2019 | 501,000.00 |
| Jun 30, 2019 | 530,000.00 |
| Mar 31, 2019 | 533,000.00 |
| Dec 31, 2018 | 494,000.00 |